Subscribe to RSS
DOI: 10.1055/a-1489-2163
Radiologisches Monitoring bei Immuntherapie des Nierenzellkarzinoms
Radiological monitoring of immunotherapy in renal cell carcinoma
Zusammenfassung
In der Radiologie stellen die Response Evaluation Criteria in Solid Tumors (RECIST 1.1) die aktuell am weitesten etablierten Bewertungskriterien für das standardisierte Therapiemonitoring bei soliden Tumoren von klassischen zytostatischen und zytotoxischen Tumortherapien dar. Der zunehmende Einsatz von Immuncheckpointinhibitoren in der Therapie des metastasierten Nierenzellkarzinoms stellt das radiologische Therapiemonitoring durch das Auftreten atypischer Ansprechmuster und immuntherapiespezifischer Nebenwirkungen vor besondere Herausforderungen. Hier können angepasste Kriterien, wie beispielsweise immune RECIST (iRECIST), bei der Verlaufsbeurteilung des Nierenzellkarzinoms helfen, sowohl innerhalb als auch außerhalb klinischer Studien atypische Verläufe unter Immuncheckpointinhibitortherapie zu erfassen.
Abstract
The Response Evaluation Criteria in Solid Tumours (RECIST 1.1) currently represent the most widely established evaluation criteria for standardised therapy monitoring in solid tumours treated with traditional cytostatic and cytotoxic tumour therapies. The increasing use of immune checkpoint inhibitors in the therapy of metastatic renal cell carcinoma poses special challenges for radiological therapy monitoring due to the presence of atypical response patterns and immunotherapy-specific side-effects. Adapted criteria such as immune RECIST (iRECIST) can help in the follow-up assessment of renal cell carcinoma to detect atypical courses of disease under immune checkpoint inhibitor therapy both within and outside of clinical trials.
Publication History
Received: 22 April 2021
Accepted after revision: 22 June 2021
Article published online:
24 August 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Referenzen
- 1 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247 DOI: 10.1016/j.ejca.2008.10.026. (PMID: 19097774)
- 2 Schwartz LH, Litière S, De Vries E. et al. RECIST 1.1 - Update and clarification: From the RECIST committee. Eur J Cancer 2016; 62: 132-137 DOI: 10.1016/j.ejca.2016.03.081. (PMID: 27189322)
- 3 Hodi FS, Hwu WJ, Kefford R. et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab. J Clin Oncol 2016; 34: 1510-1517 DOI: 10.1200/JCO.2015.64.0391. (PMID: 26951310)
- 4 Wolchok JD, Hoos A, O’Day S. et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clin Cancer Res 2009; 15: 7412-7420 DOI: 10.1158/1078-0432.CCR-09-1624. (PMID: 19934295)
- 5 Nishino M, Giobbie-Hurder A, Gargano M. et al. Developing a common language for tumor response to immunotherapy: Immune-related response criteria using unidimensional measurements. Clin Cancer Res 2013; 19: 3936-3943 DOI: 10.1158/1078-0432.CCR-13-0895. (PMID: 23743568)
- 6 Nishino M, Gargano M, Suda M. et al. Optimizing immune-related tumor response assessment: Does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?. 2014 DOI: 10.1186/2051-1426-2-17
- 7 Persigehl T, Lennartz S, Schwartz LH. IRECIST: How to do it. Cancer Imaging 2020; 20 DOI: 10.1186/s40644-019-0281-x. (PMID: 31900236)
- 8 George DJ, Kaelin WG. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003; 349: 419-421 DOI: 10.1056/NEJMp030061. (PMID: 12890838)
- 9 Kaelin WG. The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing. J Am Soc Nephrol 2003; 14: 2703-2711 DOI: 10.1097/01.ASN.0000092803.69761.41. (PMID: 14569079)
- 10 Motzer RJ, Escudier B, McDermott DF. et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373: 1803-1813 DOI: 10.1056/nejmoa1510665. (PMID: 32673417)
- 11 Motzer RJ, Tannir NM, McDermott DF. et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018; 378: 1277-1290 DOI: 10.1056/NEJMoa1712126. (PMID: 29562145)
- 12 Queirolo P, Spagnolo F. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. Cancer Treat Rev 2017; 59: 71-78 DOI: 10.1016/j.ctrv.2017.07.002. (PMID: 28756306)
- 13 Soria F, Beleni AI, D’Andrea D. et al. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. World J Urol 2018; 36: 1703-1709 DOI: 10.1007/s00345-018-2264-0. (PMID: 29549485)
- 14 Tazdait M, Mezquita L, Lahmar J. et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer 2018; 88: 38-47 DOI: 10.1016/j.ejca.2017.10.017. (PMID: 29182990)
- 15 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 2.0, 2020, AWMF Registernummer: 043/017OL. https://www.leitlinienprogramm-onkologie.de/leitlinien/nierenzellkarzinom/